Abstract
The human trophoblast cell-surface antigen 2 is expressed in a variety of malignant diseases. Using pretargeting methodology, a novel antibody against trophoblast cell-surface antigen 2 was radiolabeled and evaluated in a preclinical setting. This showed promising characteristics, lending itself as a potential basis for further clinical trials as an imaging agent and a potential theranostic. See related article by Pratt et al., p. 2719.